ArticleJournal of nanobiotechnology2025

Enzymatically responsive nanocarriers targeting PD-1 and TGF-β pathways reverse immunotherapeutic resistance and elicit robust therapeutic efficacy.

Ying-Tzu Yen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.